Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsi Talala

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
The Prostate|November 3, 2022
Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasiaLotta H Nygård, Kirsi Talala, Kimmo Taari, et al.
Acta Oncologica (Stockholm, Sweden)|November 16, 2023
Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish menAino Siltari, Teemu J Murtola, Josefina Kausz, et al.
International Journal of Cancer|January 26, 2016
5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening TrialTeemu J Murtola, Elina K Karppa, Kimmo Taari, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2017
Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohortVille Kukko, Antti Kaipia, Kirsi Talala, et al.
Prostate Cancer and Prostatic Diseases|September 21, 2022
Allopurinol and prostate cancer survival in a Finnish population-based cohortVille Kukko, Antti Kaipia, Kirsi Talala, et al.
American Journal of Epidemiology|October 26, 2016
Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate CancerTuomas P Kilpeläinen, Kirsi Talala, Jani Raitanen, et al.
Prostate Cancer and Prostatic Diseases|September 15, 2018
Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancerTeemu J Murtola, Tatu V J Kasurinen, Kirsi Talala, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2019
Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate CancerTeemu J Murtola, Samueli M Sälli, Kirsi Talala, et al.
European Urology Oncology|January 8, 2026
Effects of Causal and Noncausal Components of Screening on Prostate Cancer Mortality: A Mediation Analysis from the Dutch, Finnish, and Swedish Centers of the European Randomized Study of Screening for Prostate CancerSebastiaan Remmers, Kirsi Talala, Monique J Roobol, et al.
British Journal of Cancer|March 23, 2018
Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate CancerTeemu J Murtola, Ville Jy Vihervuori, Jorma Lahtela, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
The Prostate|November 3, 2022
Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasiaLotta H Nygård, Kirsi Talala, Kimmo Taari, et al.
Acta Oncologica (Stockholm, Sweden)|November 16, 2023
Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish menAino Siltari, Teemu J Murtola, Josefina Kausz, et al.
International Journal of Cancer|January 26, 2016
5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening TrialTeemu J Murtola, Elina K Karppa, Kimmo Taari, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2017
Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohortVille Kukko, Antti Kaipia, Kirsi Talala, et al.
Prostate Cancer and Prostatic Diseases|September 21, 2022
Allopurinol and prostate cancer survival in a Finnish population-based cohortVille Kukko, Antti Kaipia, Kirsi Talala, et al.
American Journal of Epidemiology|October 26, 2016
Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate CancerTuomas P Kilpeläinen, Kirsi Talala, Jani Raitanen, et al.
Prostate Cancer and Prostatic Diseases|September 15, 2018
Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancerTeemu J Murtola, Tatu V J Kasurinen, Kirsi Talala, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2019
Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate CancerTeemu J Murtola, Samueli M Sälli, Kirsi Talala, et al.
European Urology Oncology|January 8, 2026
Effects of Causal and Noncausal Components of Screening on Prostate Cancer Mortality: A Mediation Analysis from the Dutch, Finnish, and Swedish Centers of the European Randomized Study of Screening for Prostate CancerSebastiaan Remmers, Kirsi Talala, Monique J Roobol, et al.
British Journal of Cancer|March 23, 2018
Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate CancerTeemu J Murtola, Ville Jy Vihervuori, Jorma Lahtela, et al.
Pageof 7